Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92630 | 1.00 | MEN1 (0.54) | MEN1KMT2APOLBSMN1; SMN2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2916344 | 0.98 | MEN1 (0.53) | MEN1KMT2APOLBSMN1; SMN2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7316900 | 0.98 | MEN1 (0.53) | MEN1KMT2APOLBSMN1; SMN2SIGMAR1 | |
| Piperazine SCHEMBL28220981 | 0.98 | MEN1 (0.53) | MEN1KMT2APOLBSMN1; SMN2SIGMAR1 | |
| Cyclohexane SCHEMBL2487255 | 0.96 | MEN1 (0.51) | MEN1KMT2APOLBSMN1; SMN2SIGMAR1 | |
| SCHEMBL2189051 | 0.92 | CXCR4 (0.57) | MEN1KMT2APOLBSMN1; SMN2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL28701161 | 0.90 | CXCR4 (0.55) | MEN1KMT2APOLBSMN1; SMN2SIGMAR1 | |
| SCHEMBL16758734 | 0.87 | MEN1 (0.49) | MEN1KMT2APOLBSMN1; SMN2SIGMAR1 | |
| SCHEMBL20745043 | 0.87 | MEN1 (0.49) | MEN1KMT2APOLBSMN1; SMN2SIGMAR1 | |
| SCHEMBL31694361 | 0.87 | MEN1 (0.49) | MEN1KMT2APOLBSMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN INC (US) | 2021-04-29 | — | — | US | claimed |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2021-01-05 | — | — | US | claimed |
| EP-1742610-B1 | INTRAVITREAL IMPLANTS COMPRISING MICROSPHERES WHICH ENCAPSULATE A TYROSINE KINASE INHIBITOR AND A BIODEGRADABLE POLYMER | ALLERGAN INC (US) | 2013-06-12 | — | — | EP | claimed |
| EP-1902024-B1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | claimed |
| EP-1750665-B1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE INHIBITORS IMPLANTS | ALLERGAN INC (US) | 2012-07-11 | — | — | EP | claimed |
| US-8034957-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2011-10-11 | — | — | US | claimed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | claimed |
| US-7749530-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-07-06 | — | — | US | claimed |
| US-20100168199-A1 | Kinase Inhibitors | ALLENGAN, INC. (US) | 2010-07-01 | — | — | US | claimed |
| US-20070015748-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-01-18 | — | — | US | claimed |
| US-7015220-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-03-21 | — | — | US | claimed |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-02-02 | — | — | US | claimed |
| US-20040198802-A1 | Kinase inhibitors for the treatment of disease | ALLERGAN, INC. | 2004-10-07 | — | — | US | claimed |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ANDREWS STEVEN W (US) | 2004-10-07 | — | — | US | claimed |
| US-6765012-B2 | FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | ALLERGAN, INC. | 2004-07-20 | — | — | US | claimed |
| EP-1430048-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| US-20040102509-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | ALLERGAN, INC. | 2004-05-27 | — | — | US | claimed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003027102-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168199-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | MEN1 2293/4885KMT2A 1569/4885POLB 1863/4885 |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | MEN1 2745/4885KMT2A 958/4885POLB 2450/4885 |
| US-20040198802-A1 | Kinase inhibitors for the treatment of disease | ABL1, ERBB2, LCK | MEN1 1106/4885KMT2A 1029/4885POLB 1618/4885 |
| US-20210121397-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | MEN1 3077/4885KMT2A 1212/4885POLB 3523/4885 |
| US-20040102509-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | ABL1, ERBB2, LCK | MEN1 1106/4885KMT2A 1029/4885POLB 1618/4885 |
| US-10881608-B2 | Biodegradable intravitreal tyrosine kinase implants | KDR, PTK2B, DSTYK | MEN1 3077/4885KMT2A 1212/4885POLB 3523/4885 |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | MEN1 2745/4885KMT2A 958/4885POLB 2450/4885 |
| US-20070015748-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | MEN1 2293/4885KMT2A 1569/4885POLB 1863/4885 |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | MEN1 2745/4885KMT2A 958/4885POLB 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.